Minocycline augmentation in older adults with persistent depression: an open label proof of concept study.
Minocycline augmentation in older adults with persistent depression: an open label proof of concept study.
复制标题
DOI：
10.1017/s1041610220001313
复制
发表时间：
2020-07
影响因子：
7
通讯作者：
Alexopoulos GS
中科院分区：
文献类型：
--
作者：
Avari JN;Kanellopoulos D;Solomonov N;Oberlin L;Alexopoulos GS
接受抗抑郁药治疗的老年抑郁症患者达到缓解的不到40%。治疗反应不完全是常见的。目前的增强策略效果有限，而且许多有副作用，限制了它们在老年人中的应用。我们在经过充分的精神药物治疗后未能达到缓解的老年人中进行了米诺环素增强的首次开放试点试验。年龄大于55岁且患有重度抑郁症且在至少6周的抗抑郁治疗后抑郁症状仍未得到实质性改善的受试者，在8周的时间内给予米诺环素100mg的强化治疗，每日两次。在米诺环素强化治疗8周后，31%（4/13）的患者获得缓解。汇款人对绝望和冷漠的基线评分较高。米诺环素耐受性良好，没有不良事件或因不耐受而停药的报道。需要更大规模的安慰剂对照研究来评估二甲胺四环素增强治疗在抗抑郁药物治疗后未能达到缓解的老年人的效果。
Less than 40% of depressed older adults treated with an antidepressant achieve remission. Incomplete response to treatment is common. Current augmentation strategies have limited efficacy, and many have side effects that restrict their utilization in older adults. We conducted the first open pilot trial of minocycline augmentation in older adults who had failed to achieve remission after adequate psychopharmacologic treatment. Subjects older than 55 years of age with major depression and failure to achieve substantial improvement of depressive symptoms after at least 6 weeks of antidepressant treatment were given augmentation with minocycline 100 mg twice daily over an 8-week period. At the end of 8 weeks of augmentation with minocycline, 31% (4/13) patients achieved remission. Remitters had higher baseline ratings of hopelessness and apathy. Minocycline was well tolerated with no reported adverse events or discontinuation due to intolerance. Larger placebo-controlled studies are needed to evaluate the effects of minocycline augmentation in older adults who had failed to achieve remission after adequate treatment with antidepressants.